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Abstract: In order to reconstruct injured urinary tract tissues, biodegradable scaffolds with 
autologous seeded cells are explored in this work. However, when cells are obtained via biopsy 
from individuals who have damaged organs due to infection, congenital disorders, or cancer, this 
can result in unhealthy engineered cells and donor site morbidity. Thus, neo-organ construction 
through an alternative cell source might be useful. Significant advancements in the isolation and 
utilization of urine-derived stem cells have provided opportunities for this less invasive, limitless, 
and versatile source of cells to be employed in urologic tissue-engineered replacement. These cells 
have a high potential to differentiate into urothelial and smooth muscle cells. However, urinary tract 
reconstruction via tissue engineering is peculiar as it takes place in a milieu of urine that imposes 
certain risks on the implanted cells and scaffolds as a result of the highly cytotoxic nature of urine 
and its detrimental effect on both growth and differentiation of these cells. Both of these projections 
should be tackled thoughtfully when designing a suitable approach for repairing urinary tract 
defects and applying the needful precautions is vital. 
Keywords: urethra; tissue engineering; cytotoxicity; urinary reconstruction; urothelial cells 
 
1. Clinical Need 
The urinary tract transports urine and stores it after kidney filtration. The urinary bladder is the 
principal reservoir for urine while both ureters and urethra play the role of passageways. The unique 
feature of bladder repetitive contraction and expansion, together with a sound barrier of urine and 
potency to bear the pressure of urine make the bladder a complex organ. On the other hand, urethra 
and ureters are less complex but are still under radial pressure and shear strain of fluid during the 
transit of urine. The walls of the lower urinary tract are lined by urothelium, a multilayered epithelial 
lining which protects stroma against urine leak [1,2]. 
Several congenital and acquired pathologies can affect the human urinary tract, such as 
hypospadias, strictures, fistulas, trauma, and cancer. As a result, various reconstructive approaches 
have been utilized to restore the function of the urinary tract in these circumstances. However, certain 
factors make this process very complicated for surgeons, including poor quality of local tissues, 
which would mandate extra tissues for replacement. Additional sources of tissues, among others, 
include genital skin [3], buccal mucosa [4], and lingual mucosa [5]. However, significant 
complications, donor site morbidity, and limited tissue quantities that can be obtained from these 
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sources restrict their utilization and provide opportunities for alternative approaches, including 
tissue engineering [6]. Healthy urethra also works as a urine leakage barrier throughout micturition 
[7] and serves as a conduit for an adequate antegrade passage of seminal fluid in adult men during 
sexual intercourse [8]. The urethra has unique mechanical characteristics that arise from its elastic 
elements and smooth muscles, providing exceptional compliance that enables urine to pass under 
low resistance during voiding [9]. For the application of urological tissue engineering, several 
synthetic and natural biodegradable scaffolds, either acellular or cell-seeded, have been studied [10]. 
Scaffolds provide structural support and guide platforms for differentiated stem cells or mature cells 
to promote tissue regrowth. It has been shown that the matrices of cell-seeded collagen formed 
healthy urethra tissues, whereas collagen matrices with no cells seeded showed reduced tissue 
formation [11]. 
If the scaffolds are pre-seeded with cells, adverse outcomes such as graft shrinkage could 
potentially be avoided. However, additional challenging and time-consuming measures are required 
for harvesting, isolating, and seeding cells on scaffolds in order to seed such scaffolds [12]. 
Implantation of acellular constructs directly for the reconstruction of bladder cause graft shrinkage, 
which can be alleviated by pre-seeding cells on scaffolds. If a suboptimal tissue engineering approach 
is used without taking into consideration specific cellular functions and features, such as properties 
of biochemical urinary organs, in the regeneration of urothelium, there would be a risk of tissue 
fibrosis and formation of stones, while insufficient properties of urine barrier can develop in the 
regenerated tissues. Moreover, the long-term biological effect of such methodologies is not yet 
entirely understood [13]. 
2. Urothelium as a Urine Barrier 
Urothelium—a specialized multilayer epithelium that lines the bladder, ureter, and urethra—
provides a tight barrier for urine [13]. Normal urothelium is highly specific and has evolved to 
function in a dynamic biochemical and mechanical setting, where it contracts and stretches 
repetitively. The primary role of urothelium is to provide a barrier to solutes and ions present in urine 
and the release of chemical mediators and sensations (chemical, thermal, and mechanical sensors) 
[14]. 
The urothelium barrier is maintained through three structures, namely tight junctions situated 
between the superficial umbrella cells [15], uroplakin proteins in the membrane of the apical cell, and 
proteoglycans and urothelial glycosaminoglycan (GAG) that covers the umbrella cells. In order to 
prevent the formation of urinary tract stricture, the degeneration and formation of healthy 
urothelium containing these three structures is considered critical. Furthermore, overactivity of the 
bladder detrusor muscle, fibrosis, and inflammation are prevented by an intact urothelium regrowth 
[16]. Hence, if the urothelium is compromised, it can lead to many urologic pathologies, such as 
bladder cancer, urethral stricture, overactive bladder, recurrent urinary tract infection, and interstitial 
cystitis. Available evidence indicates that urothelial cells are more resistant to urine as compared to 
underling smooth muscle cells. In all cell lines, the toxic effect of urine has been confirmed by a real-
time analysis, and simple urine addition has been shown to result in a fast decline in cell proliferation 
[17]. In comparison to Urothelial Cells (UCs) that were substantially resistant, adipose-derived 
stromal cells (ADSCs) are the most sensitive cell type [17]. 
When the shielding barrier of the uroplakin is dysfunctional, as is the case in the early phases of 
either urothelium regeneration or healing, agents that are cytotoxic bind directly to the anionic setting 
of underlying layers. Thus, a substantial impact of deeply penetrating urine on the implanted stem 
cells’ viability could take place [16]. Since the effect of urine is harmful to cellular components of the 
tissue-engineered urethral grafts, it is vital that scaffolds have sufficient impermeability. Moreover, 
it was recently shown that interstitial fluid flow plays a significant role in the wound healing 
response, implying that any leakage of urine from within the urinary tract may provoke surrounding 
fibrosis and lead to contracture [16]. Although scaffolds with low porosity levels have excellent 
potential resistance towards the penetration of fluid and toxic solutes of urine, they may inhibit cell 
migration within these scaffolds [18,19]. 
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3. Bioengineered Urothelium 
Bioengineered urothelium would present a valuable tool for urethral replacement, as it is 
resistant to the toxic effects of urine [17,20]. Presently, limited in vitro models of urothelium exist for 
different urologic diseases within the lower urinary tract to be treated by medications. Consequently, 
there is a unique need for engineered urothelium. In vitro approaches that have been developed to 
grow urothelial cells are considered unproductive, as they last several days and yield only a few 
additional passages, thus posing a considerable time and financial constraints on high-quality 
experiments aimed at elucidating their growth mechanism, differentiation, and proliferation. 
Although much progress has been made in order to understand the response of these cells to infection 
and wounds, functional urothelium regeneration remains a crucial challenge in urinary tissue 
engineering [21,22]. 
It has been determined in many studies that urothelial cells resulting from adult stem cells show 
a sufficient quantity of markers of urothelium but often lack proper histological structure and 
functional barrier capacity [23,24]. However, due to the absence of some critical markers, such as 
uroplakin III on the apical surface and absence of tight junctions, it is understood that substituted 
cells may form an inferior epithelial barrier. 
The required in vitro urothelium cell expansion can be achieved by finding stem cell or 
progenitor cell sources that can regenerate, differentiate, and self-renew in situ. In this regard, it was 
determined that urothelial stem cells originate from upper, intermediate, or basal layers of the 
urinary tract as urine-derived stem cells [25]. Urothelial differentiation of UDSC offers a practically 
unlimited source of cells for tissue engineering. Various types of stem cells, including Mesenchymal 
Stem Cells (MSC) [24], Embryonic Stem Cells (ESC) [26], and induced pluripotent stem cell (iPSC) 
[27], have been explored towards urothelial cell differentiation. ESC or iPSC can produce functional 
urothelial cells; however, the differentiation process is time-consuming and prohibitively expensive. 
Moreover, when this process is applied, there is a risk that rare, undifferentiated cells may lead to the 
formation of teratoma. 
On the other hand, MSCs give rise to a small number of urothelial cells with less pronounced 
differentiation ability than ESC, and typically in the same germ layer lineage, leading to extraordinary 
challenges [28]. For the purpose of urinary tract repair, functional smooth muscle, endothelial, 
peripheral and urothelial neurocytes with high efficacy would be the best source of stem cells that 
would be able to differentiate, permit collection through simple, low-cost, non-invasive and safe 
method; available universally or off-the-shelf, and able to produce organ-specific or tissue-specific 
stem cells from the urinary tract. Although it is well known that some types of cells are more favorable 
than others, it is undetermined whether a perfect stem cell with these abilities exists. The most 
commonly used MSCs are ADSCs, whereas BMSCs have several limitations in tissue engineering 
applications, including short in vitro duration (<10 passages), low capacity of differentiation (<5% for 
urothelial cells of endodermal lineage) and the need for invasive collection procedures [29]. 
4. Urine-Derived Stem Cells (UDSCs) 
Urine-derived stem cells (UDSCs) can be harvested through non-invasive procedures [30] and 
sources including voided urine [22]. In order to use UDSCs successfully in tissue engineering 
approaches aimed at the reconstruction of the lower urinary tract, UDSC differentiation should be 
targeted towards three varieties of cells: urothelial cells, smooth muscles, and endothelial cells. Since 
stem cells possess remarkable regeneration capacity, many damaged tissues can be replaced by 
functional stem cells to restore normal tissue function [31]. It has been reported that by collecting 
fresh urine samples, the success rate of isolating and cultivating human urine-derived cells (HUDCs) 
can be improved. However, UDSC viability can be lost if the time of exposure is greater than 5 h, as 
pH will start to change and nutrients in urine will be lost [32]. 
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4.1. Origin of Urine-Derived Stem Cells 
UDSCs could be obtained from different species, including humans, as well as animals like 
monkeys, rabbits, and pigs. The exact sources of UDSCs will depend on the tissue supplier. In the 
kidneys, papilla or the renal tubules are the endogenous sources of stem cells. In glomeruli, the stem 
cells are obtained from glomerular parietal epithelial cells. By losing cell polarity, epithelial cells 
become mesenchymal stem cells through a process called epithelial-mesenchymal transition (EMT) 
[33]. These mesenchymal stem cells are multipotent and can be used in kidney regeneration and 
repair. These cells are characterized by high telomerase activity in comparison to other MSC types, 
making their proliferation capacity higher [31]. 
It has been shown that CD146þ/CD31 expression by UDSCs is similar to the expression of the 
same markers by podocytes and parietal cells in the glomerulus. On the other hand, epithelial cells 
of renal tubules, ureter, and bladder smooth muscle and urothelial cells do not exhibit a similar 
expression as UDSCs. These results suggest that UDSCs might be the transitional cells at the parietal 
cell/podocyte interface arising from kidney tissue [28]. 
Nevertheless, UDSCs should not be used in patients with bladder cancer because they could 
bear malignant cells. To overcome this hindrance, Bharadwaj et al. [34] have revealed that cells 
isolated from the upper urinary tract (UTCs) have characteristics similar to those of UDSCs. 
Furthermore, Chun et al. [35] pointed out that UTCs of patients with bladder cancer had no 
chromosomal anomaly or tumorigenicity in vivo. Accordingly, UTCs could be a beneficial cell origin 
for urologic tissue engineering in patients with bladder cancer. 
4.2. Advantages of UDSCs 
There are several advantages of human UDSCs relative to other stem cells. UDSCs and ADSCs 
were compared in a study conducted by Kang et al. [36] As a part of this investigation, UDSCs and 
ADSCs were collected from patients that required laparoscopic renal surgery. For each UDSC and 
ADSC type, colony formation, cell surface markers, cell proliferation, chromosome stability, immune 
modulation, and multi-lineage differentiation were investigated. In comparison to ADSCs, UDSCs 
showed an increased rate of cell proliferation, greater ability to form colonies, stronger positivity for 
stem cell marker expression, and increased efficiency for inhibition of immune cell activation [36]. 
Moreover, UDSCs showed a higher rate of myogenic, endogenic, and neurogenic differentiation. 
UDSCs have many other advantages, such as non-invasive harvest, low-cost, and straightforward 
procedures that can be used for the collection of cells. In contrast, liposuction and other invasive 
techniques are required for the isolation of MSCs, ADSCs, or hair-follicle stem cells (HFSCs) samples 
[37]. Furthermore, UDSCs (excluding UTI and anuria) can be obtained irrespective of the age, sex, 
and health status of an individual. Enzyme digestion is not required to sequester pure stem cells, 
while UDSCs exhibit telomerase activity, and they differentiate with higher efficacy into smooth 
muscle, urothelial, and endothelial cells. Table 1 details the advantages and characteristics of UDSCs 
in comparison to other SCs utilized in urological regenerative medical purposes. 
Table 1. Comparison of different stem cell types used for urological repair. MSC, mesenchymal stem 
cell; SMC, smooth muscle cell; UC, urothelial cell; UDSC, urine-derived stem cell. ADSC, adipose-
derived stromal cell; BMSC, bone marrow-derived mesenchymal stromal cell; ESC, embryonic stem 
cell; iPSC, induced pluripotent stem cell; N/A, Not applicable. 
Features 
Cell Type 
UDSCs 
[25,35,38–42] 
iPSCs/ESC 
[43,44] 
Bladder 
SMC, UCs 
[45,46] 
ADSCs [47,48] BMSCs [23,29,49–51] 
Harvesting 
technique 
Non-invasive, 
Low-cost, Easy 
Invasive Invasive Invasive Invasive 
Stem cell isolation Very Easy Easy N/A Neutral Neutral 
Angiogenic trophic 
factors 
Yes Unknown Limited Yes Yes 
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Immuno-
modulatory 
properties 
Yes Unknown Unknown Yes Yes 
Oncogenic 
potential 
No Yes No No No 
Telomerase 
activity 
75% of UDSC 
have 
Telomerase 
Activity 
Have 
Telomerase 
Activity 
No 
Telomerase 
Activity 
Unknown Unknown 
Endothelial and 
urothelial 
differentiation 
capability 
High Ability 
(60–85%) 
Yes N/A Yes Yes 
Multi-lineage 
differentiation 
capability 
Multipotent Pluri-potent N/A 
Multipotent 
(mesodermal 
cell lineages) 
Multipotent 
(mesodermal 
cell lineages) 
Self-renewal 
capability 
High 
Capability 
Strong 
Capability 
Capable Unknown Capable 
4.2.1. Cell Proliferation and Differentiation 
UDSCs show a higher rate of myogenic, endogenic, and neurogenic differentiation and a lower 
osteogenic, adipogenic, and chondrogenic differentiation rate in comparison to ADSCs. Therefore, 
UDSCs instead of ADSCs can be used as an autologous stem cell source for muscle, neuron, and 
endothelial tissue reconstruction [36]. Available evidence indicates that UDSCs have efficient 
cappacity of multipotent differentiation into cells of cartilage, bone, muscles, and fat [42]. Hence, 
UDSCs are a viable source of cells for the treatment of erectile and renal dysfunction and various 
diseases, as well as bladder tissue engineering. 
Urothelial differentiation of UDSCs presents an almost limitless cell source for tissue 
engineering or model fabrication with simple methods that can be used to isolate and expand urine 
cells. Additionally, the possibility of producing cells from urine samples makes the human urine-
derived cells a smart choice for cell therapy [52]. This can produce high-quality cells, which can be 
expanded extensively [42]. Approximately 140 clones of UDSCs in 24-h urine collection from a single 
healthy individual can be attained [39]. Hence, 24-h urine output can yield > 1 × 108 cells over three 
passages. This number is adequate for most of the intended applications. Moreover, as enzymes like 
collagenase are not needed for cell dissociation, cell viability during isolation is preserved [34,39]. In 
addition, numerous in vivo studies have failed to provide any evidence in human UDSCs for the 
potential oncogenic effect [38,51]. UDSCs are innate to the urinary tract, and with urine contact, they 
can survive similarly as healthy urothelial cells. 
It has been shown that cell subpopulation isolated from urine could differentiate into numerous 
bladder cell lineages and exhibit features of progenitor cells. In an experiment conducted by Zhang 
Y et al. [40], three phenotypes were shown by isolated cells, i.e., progenitor-like cells, differentiating, 
and completely differentiated. Cells that were single progenitor could differentiate into the lineages 
of cells that express smooth muscle, urothelial, interstitial, and endothelial cell markers. Hence, cells 
derived from urine can be used as an alternative source for tissue engineering and urinary tract 
reconstruction. 
The urothelial differentiation was shown to induce the expression of uroplakin-III, the anion 
exchange proteins AE3 and AE1, cytokeratin (CK) 7, and myosin, desmin, and smoothelin [38]. 
Additionally, when co-culturing of urothelial differentiated UDSCs and myogenically-differentiated 
UDSCs was done on decellularized collagen matrix-like SIS or bladder submucosa, UDSC in vitro 
structure was similar to that of the bladder wall [40,53]. 
Epithelialization process of graft implantation takes almost seven days following the 
augmentation of the urinary tract wall. Urothelium starts as a monolayer for the complete coverage 
of the luminal graft surface. It then gradually transforms into normal multilayered urothelium not 
distinguishable from healthy surrounding tissues. Urothelium impermeability is highly dependent 
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on cell-cell interactions [54]. Thus, the formation of tight cell-cell interactions on the luminal surface 
of a scaffold material is essential to the formation of a proper cellular barrier. It is, therefore, pertinent 
to divert urine during the first week from implantation of a tissue-engineered graft. 
4.2.2. Self-Renewal Capability 
Research on stem cell deliver promising approaches in improving healthcare for human beings 
[55]. Self-renewal capability is the ability of the stem cells to divide in order to make new stem cells 
and thus expand the stem cell pool. Therefore, a source of stem cells with high multipotent 
differentiation and self-renewal capacities that can be attained through approaches that are not only 
simple but also non-invasive is very desirable. UDSCs have the self-renewal capability, which is 
higher at the initial passages, such as passage 2 or 3 [39] Zhang et al. [31] found that cell 
subpopulation isolated from urine shares many characteristics with MSCs, like cell growth patterns, 
expansion capacity, clonogenicity, the expression profile of cell surface marker and multipotent 
differentiation capacity. 
4.2.3. Colony Formation 
Kang et al. [36] showed that colony formation showed three times more UDSCs value colony 
formation in comparison with ADSC. It has also been reported that 5 to 10 colonies of UDSCs can be 
produced per 100 mL fresh urine [34] and in every 100 mL sample, 6 to 7 clones of USC existed in 
urine that was collected fresh, 3 to 4 clones of UDSC existed in urine that was preserved for 24 h, and 
4 to 5 UDSC clones existed in urine that was preserved for 12 h [39]. 
4.2.4. Vascularization Ability of UDSCs 
Through IL-6 and IL-8 secretion and inhibition of T and B cells and peripheral blood 
mononuclear cells (PBMNC), UDSCs can produce immunomodulatory effects. IL-6 and IL-8 
concentration is higher in UDSC supernatant in contrast to BMSC supernatant when human cytokine 
release arrays are stimulated. In the future, for the prevention and treatment of diabetic bladder tissue 
lesions or any other immune system disorder, IL-6 and IL-8 can be the principal immunomodulatory 
cytokines [31]. Moreover, if the microenvironment is favorable, angiogenic growth factors can be 
secreted by UDSCs, as VEGF can improve grafted cells’ survival. It can also help in myogenic 
differentiation and enhance innervations [39]. 
Zhang D et al. [31] showed that using genetically modified stem cells via VEGF transfection gene 
considerably promoted myogenic differentiation of UDSCs and induced innervation and 
angiogenesis. However, adverse side-effects such as hyperemia, hemorrhage, and even death were 
seen in the animal model due to the viral delivery of VEGF. UDSCs secrete almost 25 types of 
angiogenic paracrine growth factors that include VEGF, FGF, IGF, HGF, PDGF, and MMP. 
Angiogenic and immunomodulatory growth factors from UDSCs play a significant role in 
vascularization [37]. 
4.2.5. Extracellular Vesicles Secreted by UDSCs 
Extracellular vesicles (EVs) include exosomes and microvesicles that have significant beneficial 
effects in several models of disease [56]. Exosomes from both MSCs and ADSCs have been shown to 
lessen CNIED (cavernous nerve injury-induced erectile dysfunction) [57,58]. EVs, including 
microvesicles and exosomes, are critical components in the paracrine secretion of stem cells. Exosome 
production by human UDSCs can suppress kidney complications in diabetic rats. Moreover, storing 
and managing EVs is much easier in comparison to stem cells, in order to decrease the chance of 
formation of a tumor as lower clearance of EVs enhances tumor formation [59]. Prattichizzo et al. 
proposed that EVs can treat endothelial metabolic memory through the delivery of miRNA [60]. 
In a study conducted by Ouyang B et al. [59], it was presented that reduce deposition of UDSC-
EVs enhanced the improved neurogenic-mediated erectile reaction in diabetic erectile dysfunction 
and endothelial cell marker expression. The erectile response enhancement was indicated by 
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improved ICP/MAP and ICP ratio, which was attributed to enhanced smooth muscle and 
endothelium function.  
There are many advantages of exosome-meidated therapy. Exosome faciliates cell-to-cell 
interaction through the transfer of molecules such as nucleic acid, lipids, and proteins. Since 
exosomes are nanosized, they can easily penetrate different bio barriers, including the blood-brain 
barrier. Hence, exosome-mediated therapy provides treatment of earlier distant foci of disease [61]. 
4.3. Markers of UDSCs 
UDSCs have expressed MSC markers, as well as other important cell surface markers. In a study 
conducted by Tayhan SE et al., it has been shown that urine-derived cells (UDCs) contain both stem 
cells as well as urothelial cells. As a maker of urothelial cells, cytokeratin 7 was used, whereas a 
negative and positive marker for mesenchymal stem cells of human, CD90, and CD45, respectively, 
were used [32]. ADSCs and UDSCs have shown a similar positive display of approximately more 
than 92% for CD73, and CD44 while ADSCs showed higher expression for CD105 and CD90. 
Immunogenic and hematopoietic markers showed negative manifestation on ADSCs as well as 
UDSCs [29]. In another study, it was shown that UDCs also exhibit CD44, CD29, CD54, CD90, CD73, 
CD105, CD166, and CD146, which are surface markers for MSC. UDCs also express markers of 
embryonic stem cells that include c-Myc, klf4, and Oct4. HLD-DR, CD34, CD11b, CD45, CD14, CD31 
and CD19 are markers of hematopoietic stem cells that are not expressed by UDCs [38]. 
4.4. Limitations of UDSCs 
Despite many UDSC benefits, there are numerous challenges too [62]. Can adult SCs 
transdifferentiate in vivo, replenishing the deteriorated tissues, or produce some growth factors 
which help in the regeneration of tissues of the host? [47] UCs seeded on the side of the lumen of the 
scaffold are usually washed out through urine, lost during surgery, or ejected mechanically through 
urethral catheter. Additionally, cells that were successfully retained begin to die within the first week, 
probably due to inflammation, ischemia, or detachment from the extracellular matrix because of 
apoptosis [30]. One of the limitations of UDSCs is that urothelial cells cannot be obtained from 
patients with bladder infection, urethral stricture issues, or trauma. Moreover, urothelial cells in some 
patients may be affected by bladder stones or some other foreign bodies that can pose challenge to 
the expansion and isolation of a sufficient population of cells. 
The influence of urine on UDSCs after in vitro expansion has not been studied to date. However, 
considering their source, they are probably more resistant to urine relative to other cell types. 
Studying the mechanism of this possible resistance would be very beneficial to increase cell 
surveillance after implantation. Until the layer of urothelial regenerates, stem cells are exposed to 
urine. It takes a week for the regeneration of urothelium; during that time, seeded cell grafts absorb 
urine. 
The unique challenge in using cells in reconstructive development is whether the cells are robust 
enough to survive the pressure of the urine and layered structure while retaining functionality. This 
would result from reciprocal interaction between the cells and the biomaterials used for urinary 
conduits, and functional studies need to be carried out. However, scaffolds or biomaterials containing 
urothelial cells and smooth muscle cells differentiated from UDSCs can be promising media for 
urinary reconstruction [13]. 
5. Urine-Derived Stem Cells in Urethral Regeneration 
Urethral reconstruction using cell-seeded methods with autologous cells seeded on 
biodegradable scaffolds achieves better outcomes in longer segment urethra repair [63,64], compared 
to non-seeded scaffolds. A suitable cell origin and biomaterial scaffold are both crucial for urethra 
tissue engineering. Oral mucosa [65] is currently most commonly utilized for urethral tissue 
engineering. 
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UDSCs were utilized in several preclinical and human experiments aimed at tissue engineering 
applications for urethral repair. Urine was collected through urethral catheterization, spontaneous 
voiding, bladder washing, or bladder irrigation. Cells were cultured in initiation media following 
centrifugation of the urine samples. Findings yielded indicate that 5−10 UDSC clones/100 mL urine 
can be collected from majority of freshly voided urine samples [38]. To prepare a cell-seeded 
biomaterial scaffold for use in urological tissue regeneration, about 50 × 106 cells/cm3 must be 
available for seeding. Thus, a 200 mL urine sample can provide enough cells to create a cell-seeded 
scaffold 0.5 × 2 × 10 cm3 in size (Figure 1). 
 
Figure 1. Urine-derived stem cells (UDSC). Isolated primary cells (a) and confluent first passage (b) 
colonies. Flattened third passage cells (c) contaminated with renal epithelial cells. A representative 
histogram showing UDSCs positive for mesenchymal stem cells markers, including CD-90, CD-146, 
CD-73, CD-105, CD-271, and lack of CD14, CD34, CD45, and CD20 endothelial cell expression (d). 
Reproduced with permission from [66]. 
Tayhan et al. [32] studied both UDSCs and human urothelial cells that were isolated from fresh 
urine samples after been harvested from six healthy patients via catheterization. Using 
immunohistochemical assessment, UDSCs reached confluency within 12 days and were positive for 
cytokeratin 7. Mesenchymal stem cells were also positive for CD90 and CD45. Yang et al. [67] used 
flow cytometry, immunocytochemistry, and cell proliferation assay to characterize UDSCs harvested 
from rabbits through either voided urine or bladder washes. Successful differentiation into urothelial, 
smooth muscle, and osteogenic cell lines was achieved. 
UDSCs from voided urine seeded into small intestinal submucosa (SIS) were tested by Yang et 
al. and showed differentiation into smooth muscle and urothelial cells. Both static and dynamic 
culturing approaches were employed by the authors before in vivo implantation. Dynamic conditions 
resulted in the formation of a multilayered mucosal structure similar to urothelial tissue. [40] On the 
other hand, autologous rabbit UDSCs harvested via bladder irrigation were labeled with PKH67 and 
seeded into SIS by Wu et al. [40] Cell-loaded scaffolds implanted into rabbits to repair ventral urethral 
defect showed differentiation of the cells and regeneration of the urethral defect. [68] (Figure 2) 
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Figure 2. Histopathological evaluation of urothelium regeneration. H&E (a) and AE1/AE3 IHC (b). 
The USC-seeded 5% PAA-treated SIS group showed better multilayered urothelial tissue over the 
different time frames in comparison to 5% PAA-treated SIS only group. (c) Infiltration of 
inflammatory cells (arrow) and fibrosis (*) were observed in the 5% PAA-treated SIS only group. Scale 
bar = 200 μm. (d) Image analysis of the AE1/AE3-positive area to the total area at each time point in 
the two groups. *Statistically significant (p <  0.05). m: months, USC: urine-derived stem cell, w: weeks. 
Reproduced with permission from [68]. 
Yang et al. also seeded UDSCs with dynamic culture on bladder submucosa, which significantly 
promoted cell-matrix penetration in vitro, as well as cell growth in vivo [69]. Bodin et al. seeded 
UDSCs on microporous bacterial cellulose (BC), obtaining layered urothelial cells and SMCs with 
excellent cell-matrix infiltration [55]. Dynamic conditioning was performed on culturing human 
UDSCs and seeded on SIS formed multilayered uroepithelium in vitro using a Transwell system. 
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Excellent cell differentiation was observed, and the permeability assay confirmed healthy functioning 
of the urothelial barrier [28] (Figure 3). 
 
Figure 3. Formation of multilayered urothelium of urothelial cell-induced urine-derived stem cells. 
Under dynamic culture, the urothelium stained positive for AE1/AE3 like urothelium onto a Small 
intestinal submucosa (SIS) scaffold. In contrast, USC treated with EGF or SMC/CM produced a thinner 
layer, and USC alone formed a single layer. Scale bar = 50 μm. Abbreviations: USC = urine-derived 
stem cells, UC = urothelial cells, SMC = smooth muscle cells, CM = conditioned medium, 
UC/CM = urothelium conditioned medium, SMC/CM;smooth muscle cell-conditioned medium, 
EGF;epidermal growth factor. Reproduced with permission from [28]. 
6. Urine Cytotoxicity 
Although somewhat less complex than the urinary bladder, both the urethra and ureters have 
related structural, functional, and physical characteristics. These tissues are subjected to both radial 
and fluid shear forces as a result of urine propulsion, transport, and storage. Additionally, these 
tissues have a lining of epithelial cells called urothelium that guards the underlying tissues against 
urine, which was recognized to be one of the very significant factors contributing to implanted cell 
survival when conducting urethral tissue engineering. 
Singh and Blandy conducted an experimental study on rats to determine the role of urine 
extravasation in the urethral stricture pathogenesis [70]. They observed that the ultrastructure of 
urethral stricture tissue suggested that some strictures were fibrous while others were more resilient, 
and the total amount of collagen increased in urethral strictures, resulting in dense fibrotic tissue with 
decreased smooth muscle tissue and decreased elasticity. 
Therefore, urine is considered a profoundly cytotoxic agent whose effect in urologic tissue 
engineering has been undervalued. Studies conducted in vitro on MSCs and urothelial cells cultured 
in a mixture of urine exhibited tremendous cytotoxicity [71,72]. The recognized cytotoxic impact was 
not particular for MSC as an experiment showing urine cytotoxic consequences on human urothelial 
cells was conducted by Davis et al. [71] Those outcomes confirm the central role of urine in the 
pathogenesis of interstitial cystitis (IC), a condition that manifests as repetitive discomfort in the 
bladder and the surrounding pelvic area. While the precise root cause of IC has not yet been 
established, it is known to hinder bladder cell generation and make the healing of cell layers very 
challenging. 
When cells are seeded on the scaffold on the side facing urethra lumen, they are directly exposed 
to urine, particularly those situated on the inner surface of the biomaterial. Urine is rich in protamine 
sulfate, products of low molecular weight, and cationic substances that are chiefly responsible for its 
nonselective and high cytotoxicity. High urea levels, a principal constituent of urine, are associated 
with a more significant reduction in endothelial progenitor cells (EPCs), a bone-marrow-derived 
mononuclear cell population that plays a vital role in the preservation of vascular integrity, 
availability, and function [63]. Recently, Trecherel et al. [73] demonstrated that urea was able to 
induce the expression of a pro-apoptotic member of the BCL2 family, the Bcl-xL/Bcl-2-associated 
death promoter (BAD) protein, in VSMC. Likewise, urea was shown to be toxic for HeLa Cells and, 
in contrast to the initial single wave of arrested mitosis seen with continuous exposure to urea, 
intermittent exposure resulted in successive peaks of arrested metaphases and had significantly more 
remarkable effects on the growth and viability of the cultures [74]. 
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In addition, Adamowicz et al. demonstrated that none of the cells seeded on the lumen side of 
the urinary tract survive beyond 24 h post-transplantation. Although in this experiment, the pH of 
the medium of cultivation was corrected to 7.4, the urine cytotoxic properties might be faster in a 
physiological environment when there is an acidic pH (which can be even 5.0). Valuable information 
was gained from this study when pursuing urinary tract repair using cellular grafts [72]. Therefore, 
it is critical to implement appropriate urinary diversion when implanting a scaffold within the 
urinary tract to guard against these unwanted outcomes of urinary leakage into surrounding tissues 
and allow a healthier healing process to take place. 
7. Conclusion 
Great efforts and significant milestones were achieved in the pathway to attain the maximum 
benefit of stem cells derived from urine with its inherent fitting characteristics given the ease and 
limitless nature of this highly versatile fuel source for the cellular component of scaffolds. Still, further 
studies are needed to better understand and limit the adverse effects of urine on the implanted 
bioengineered constructs and thus improve subsequent outcomes of tissue-engineered replacements 
of the urinary tract. 
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